Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study

M. Peiskerová, M. Kalousová, V. Danzig, B. Míková, M. Hodková, E. Němeček, A. Bani-Hani, D. Ambrož, H. Benáková, A. Linhart, T. Zima, V. Tesař,

. 2013 ; 14 (-) : 142.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND: Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the development of LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible association of PlGF and several other CV risk markers to echocardiographic parameters in CKD population. METHODS: We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2-4. Mean follow-up was 36 ±10 months. Laboratory and echocardiographic data were collected 2-3 times, at the shortest interval of 12 months apart. Multivariate regression analysis was used to detect independent correlations of variables. RESULTS: Increased left ventricular mass index (LVMI, g/m2.7) was found in 29% patients with CKD 2-4, left ventricular (LV) diastolic dysfunction was detected in 74.1% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 30.6% patients). After 36 ± 10 months increased LVMI was found in 37.1% patients with CKD 2-4, LV diastolic dysfunction was detected in 75.8% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 32.3% patients). Following independent correlations were found: LVMI was related to PlGF, cholesterol, BNP, systolic blood pressure and serum creatinine. EN-RAGE correlated positively with left atrial diameter and inversely with E/A ratio. During the follow-up we found a significant increase in LVMI and left atrial diameter, whereas a significant decrease in LVEF was noted. CONCLUSION: According to our data, PlGF is independently related to increased LV mass in CKD, whereas EN-RAGE is more likely related to diastolic dysfunction in this population.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14050915
003      
CZ-PrNML
005      
20140408114412.0
007      
ta
008      
140401s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/1471-2369-14-142 $2 doi
035    __
$a (PubMed)23844967
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Peiskerová, Martina
245    10
$a Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study / $c M. Peiskerová, M. Kalousová, V. Danzig, B. Míková, M. Hodková, E. Němeček, A. Bani-Hani, D. Ambrož, H. Benáková, A. Linhart, T. Zima, V. Tesař,
520    9_
$a BACKGROUND: Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the development of LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible association of PlGF and several other CV risk markers to echocardiographic parameters in CKD population. METHODS: We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2-4. Mean follow-up was 36 ±10 months. Laboratory and echocardiographic data were collected 2-3 times, at the shortest interval of 12 months apart. Multivariate regression analysis was used to detect independent correlations of variables. RESULTS: Increased left ventricular mass index (LVMI, g/m2.7) was found in 29% patients with CKD 2-4, left ventricular (LV) diastolic dysfunction was detected in 74.1% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 30.6% patients). After 36 ± 10 months increased LVMI was found in 37.1% patients with CKD 2-4, LV diastolic dysfunction was detected in 75.8% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 32.3% patients). Following independent correlations were found: LVMI was related to PlGF, cholesterol, BNP, systolic blood pressure and serum creatinine. EN-RAGE correlated positively with left atrial diameter and inversely with E/A ratio. During the follow-up we found a significant increase in LVMI and left atrial diameter, whereas a significant decrease in LVEF was noted. CONCLUSION: According to our data, PlGF is independently related to increased LV mass in CKD, whereas EN-RAGE is more likely related to diastolic dysfunction in this population.
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hypertrofie levé komory srdeční $x krev $x ultrasonografie $7 D017379
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a těhotenské proteiny $x krev $7 D011257
650    _2
$a prospektivní studie $7 D011446
650    _2
$a chronická renální insuficience $x krev $x ultrasonografie $7 D051436
650    _2
$a dysfunkce levé srdeční komory $x krev $x ultrasonografie $7 D018487
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kalousová, Marta $u -
700    1_
$a Danzig, Vilem $u -
700    1_
$a Míková, Blanka $u -
700    1_
$a Hodková, Magdalena $u -
700    1_
$a Němeček, Eduard $u -
700    1_
$a Bani-Hani, Amjad $u -
700    1_
$a Ambrož, David $u - $7 gn_A_00005417
700    1_
$a Benáková, Hana $u -
700    1_
$a Linhart, Ales $u -
700    1_
$a Zima, Tomas $u -
700    1_
$a Tesař, Vladimir $u -
773    0_
$w MED00008194 $t BMC nephrology $x 1471-2369 $g Roč. 14, č. - (2013), s. 142
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23844967 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140401 $b ABA008
991    __
$a 20140408114459 $b ABA008
999    __
$a ok $b bmc $g 1018051 $s 849495
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 14 $c - $d 142 $i 1471-2369 $m BMC nephrology $n BMC Nephrol $x MED00008194
LZP    __
$a Pubmed-20140401

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...